Ligand Updates License Agreement with Exelixis
News Nov 03, 2009
Ligand Pharmaceuticals Incorporated has amended its license agreement with Exelixis, Inc. as a result of which Ligand is now entitled to receive royalties on net sales of future products from a mineralocorticoid receptor program and a one-time $75,000 payment for providing access to certain patent rights. Also, as a result of Ligand’s settlement with Salk last year, the amendment eliminated certain minimum annual royalties that may have been payable by Exelixis.
The agreement originated in 1999 when Ligand invested in and licensed certain technologies to X-Ceptor, a private company subsequently acquired by Exelixis.
As a result of the amendment, Ligand is now entitled to receive a royalty for the mineralocorticoid receptor program in preclinical studies targeting metabolic disease that Exelixis previously partnered with Daiichi Sankyo.
By leveraging an organ-on-a-chip model and a bioreactor, four human gut metabolites have been identified that can help explain the enhanced sensitivity of the human colon towards enterohemorrhagic E. coli, which is responsible for more than 100,000 infections per year in the USA alone.READ MORE